InvestSMART

The article you are trying to access does not exist, however, here are some articles you may be interested in.

Challenger - Janus Global Life Sciences - Managed Fund (Closed)

Fund Objective
To seek long-term growth of capital.
Fund Strategy
Invests primarily in equity securities of US and non-US companies selected for their growth potential. Under normal circumstances, it invests at least 65% of its total assets in securities of companies that Janus believes have a life science orientation. As a fundamental policy, the Fund normally invests at least 25% of its total assets, in the aggregate, in the following industry groups: health care, pharmaceuticals, agriculture, cosmetics/personal care, and biotechnology.

Fund Performance Comparison

Relative Fund Performance vs {{ fund.benchmark.peers.peerCount }} peers using {{ fund.benchmark.name }} as their benchmark.

{{ fund.name }}
Peers
Benchmark ({{ fund.benchmark.name }})
{{ fund.model.name }}
The performance of the peers is calculated as the total of the performance for each time period for all the funds in the peer group, divided by the number of funds in the peer group.

Fees Comparison

{{ fund.mer | number:2 }}
% p.a.
{{ fund.name }}
{{ modelPortfolio.mer * 100 | number:2 }}
% p.a.
{{ modelPortfolio.name }}
{{ fund.benchmark.peers.mer * 100 | number:2 }}
% p.a.
Average of peers ({{ fund.benchmark.peers.peerCount }})
NOTE: Fee data has been provided by Morningstar, it may not include all costs being charged on your investment such as platform and adviser fees. You should check your fund manager or adviser statements to find out the exact fees you are being charged. Peers are funds that use the same benchmark in the Morningstar database.
Upsell Banner

Fund performance

  1M 3M 6M 1Y p.a. 2Y p.a. 3Y p.a. 5Y p.a. 10Y p.a.
Total return -5.81% -5.79% -12.35% 4.22% -3.62% -13.78% -% -%
Growth return -5.81% -5.79% -12.35% 4.22% -3.62% -13.78% -% -%
Income return 0% 0% 0% 0% 0% 0% -% -%
Market index (MSCI World Ex Australia NR AUD)
Total return -2.51% -6.22% -3.83% 8.14% 10.17% 16.04% 12.71% 13.19%
As at 31 Oct 2004. Returns for periods greater than 1 year are annualised. All figures are percentages.

Asset Allocation

Challenger - Janus Global Life Sciences
International Equities
99.60%
Cash
0.40%
Australian Equities
0%
Property & Infrastructure
0%
Fixed Interest
0%
Alternatives
0%
Average Allocation of Peers
International Equities
91.07%
Cash
1.79%
Australian Equities
6.64%
Property & Infrastructure
0.21%
Fixed Interest
-0.01%
Alternatives
0.29%

General Information

Fund Details
Type Description
Challenger - Janus Global Life Sciences
Closed
Fidante Partners Limited
HOW0109AU
Equity World Other
Not Rated
Investment Fund
31 May 2001
$2.21 million (as at 28 Feb 2002)
$21.5246 (as at 1 Nov 2004)
$21.2616 (as at 1 Nov 2004)
Finalised
Offer information
Type Description
Minimum initial investment $5,000.00
Your guide to next steps

Dealing with a struggling fund? What to Do and Look For

Your managed fund switching checklist. Is fear of capital gains tax holding you back?
Your managed fund switching checklist. Is fear of capital gains tax holding you back?
The Great Investment Fee Scam is hiding in plain sight. And it's ripping us all off.
The Great Investment Fee Scam is hiding in plain sight. And it's ripping us all off.
Guide to tidying up your Portfolio Manager holdings
Guide to tidying up your Portfolio Manager holdings

FAQs about the Challenger - Janus Global Life Sciences

The objective of the Challenger - Janus Global Life Sciences managed fund is To seek long-term growth of capital.

The strategy of the Challenger - Janus Global Life Sciences managed fund is Invests primarily in equity securities of US and non-US companies selected for their growth potential. Under normal circumstances, it invests at least 65% of its total assets in securities of companies that Janus believes have a life science orientation. As a fundamental policy, the Fund normally invests at least 25% of its total assets, in the aggregate, in the following industry groups: health care, pharmaceuticals, agriculture, cosmetics/personal care, and biotechnology.

The APIR code of the Challenger - Janus Global Life Sciences managed fund is HOW0109AU.

Challenger - Janus Global Life Sciences’s total return last month was -5.81%. This was made up of a growth return of -5.81% and an income return of 0%. These returns were calculated as at 31 Oct 2004.

Challenger - Janus Global Life Sciences’s total return for the last three months was -5.79%. This was made up of a growth return of -5.79% and an income return of 0%%. These returns were calculated as at 31 Oct 2004.

Challenger - Janus Global Life Sciences’s one-year total return is 4.22%. This was made up of a growth return of 4.22% and an income return of 0%. These returns were calculated as at 31 Oct 2004.

Challenger - Janus Global Life Sciences’s one-year total return is -13.78%. This was made up of a growth return of -13.78% and an income return of 0%. These returns were calculated as at 31 Oct 2004.

The asset allocation of the Challenger - Janus Global Life Sciences managed fund is :

International Equities
99.60%
Cash
0.40%
Australian Equities
0%
Property & Infrastructure
0%
Fixed Interest
0%
Alternatives
0%

The Responsible Entity for the Challenger - Janus Global Life Sciences managed fund is Fidante Partners Limited.

The Challenger - Janus Global Life Sciences managed fund belongs to the Equity World Other sector/asset class.

As at 28 Feb 2002, the size of the Challenger - Janus Global Life Sciences managed fund was $2.21 million.

The Challenger - Janus Global Life Sciences managed fund has an inception date of 31 May 2001.

The current entry price of the Challenger - Janus Global Life Sciences managed fund is $21.5246 per unit and the current exit price is $21.2616 per unit (as at 1 Nov 2004).

The current exit price of the Challenger - Janus Global Life Sciences managed fund is $21.2616 per unit and the current entry price is $21.5246 per unit (as at 1 Nov 2004).

The minimum initial investment amount for the Challenger - Janus Global Life Sciences managed fund is $5,000.

Fund data sourced from Morningstar. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. Whilst every care has been taken in producing these numbers, neither Morningstar nor InvestSMART can make any guarantees around the complete accuracy of these figures. Should you decide to change investments, please read all relevant disclosure documents including the Product Disclosure Statements and if required, you may consider speaking to a financial professional for further guidance. A tax event may be realised as a result of switching investments. Past performance is not a reliable indicator of future performance.